HUM vs PFE
Humana · Pfizer
| HUM Humana Healthcare | PFE Pfizer Healthcare | |
|---|---|---|
| Market | ||
| Price | $414.50 -0.73% | $30.52 +1.90% |
| Market cap | $49.8B | $174.0B |
| P/E (TTM) | 38.9 | 40.1 |
| Dividend yield | 0.68% | 5.38% |
| 52-week range | $163.11 – $456.50 | $23.62 – $30.67 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Humana’s 22% Medicare Advantage Membership Growth Is Being Dismissed As A Liability — The… Jul 10, 2026 | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 |
| Latest earnings | ||
| Reported | — | — |
| Revenue | — | — |
| EPS | — | — |
| Guidance | — | — |
| Revenue growth, last 4 reports | — | — |
| Topics | ||
| Main topics | ||
| Company page | Company page | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.